IL238415B - Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e - Google Patents

Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e

Info

Publication number
IL238415B
IL238415B IL238415A IL23841515A IL238415B IL 238415 B IL238415 B IL 238415B IL 238415 A IL238415 A IL 238415A IL 23841515 A IL23841515 A IL 23841515A IL 238415 B IL238415 B IL 238415B
Authority
IL
Israel
Prior art keywords
misregulated
eif4e
treating
compounds
disorders associated
Prior art date
Application number
IL238415A
Other languages
English (en)
Hebrew (he)
Other versions
IL238415A0 (en
Inventor
Patane Michael
Original Assignee
Patane Michael
Bantam Pharmaceutical Llc
Egenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patane Michael, Bantam Pharmaceutical Llc, Egenix Inc filed Critical Patane Michael
Publication of IL238415A0 publication Critical patent/IL238415A0/en
Publication of IL238415B publication Critical patent/IL238415B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL238415A 2012-10-22 2015-04-21 Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e IL238415B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716987P 2012-10-22 2012-10-22
US201261735458P 2012-12-10 2012-12-10
PCT/US2013/066041 WO2014066304A1 (en) 2012-10-22 2013-10-22 Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Publications (2)

Publication Number Publication Date
IL238415A0 IL238415A0 (en) 2015-06-30
IL238415B true IL238415B (en) 2018-04-30

Family

ID=50545165

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238415A IL238415B (en) 2012-10-22 2015-04-21 Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e

Country Status (7)

Country Link
US (1) US9409901B2 (enExample)
EP (1) EP2909203A4 (enExample)
JP (1) JP2015534990A (enExample)
AU (1) AU2013334860B2 (enExample)
CA (1) CA2888889A1 (enExample)
IL (1) IL238415B (enExample)
WO (1) WO2014066304A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349962A (zh) * 2015-06-01 2018-07-31 班塔姆制药有限责任公司 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法
CN110769823A (zh) 2016-11-30 2020-02-07 班塔姆制药有限责任公司 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
MX2019006299A (es) * 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
CN114340678A (zh) * 2019-09-03 2022-04-12 索瓦尔基因股份有限公司 用于诊断或治疗与elf4e活性增加相关的病症的包含elf4e抑制剂的组合物
WO2021067752A1 (en) * 2019-10-04 2021-04-08 Yale University Targeting cap-dependent translation to reduce seizures in mtor disorders
US11753403B2 (en) * 2020-03-03 2023-09-12 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
NZ550114A (en) * 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
WO2006078942A2 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
GB0614070D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0614068D0 (en) 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
EP2078004B1 (en) * 2006-10-31 2015-02-25 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
AU2008282885A1 (en) * 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
WO2012006068A2 (en) 2010-06-28 2012-01-12 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation

Also Published As

Publication number Publication date
US9409901B2 (en) 2016-08-09
AU2013334860A1 (en) 2015-05-14
EP2909203A1 (en) 2015-08-26
EP2909203A4 (en) 2016-04-06
WO2014066304A1 (en) 2014-05-01
IL238415A0 (en) 2015-06-30
JP2015534990A (ja) 2015-12-07
AU2013334860B2 (en) 2018-02-15
US20150274717A1 (en) 2015-10-01
CA2888889A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
IL263661A (en) Combination therapy for the treatment of glioblastoma
SMT201700531T1 (it) Derivati estrogeni per uso nel trattamento di disordini neurologici
ZA201501390B (en) Compounds for the treatment of mtor pathway related diseases
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
IL235317A0 (en) A compound for the treatment of metabolic disorders
IL250725B (en) Difluorolactam formulations for ep4-mediated bone-related conditions and diseases
IL238415B (en) Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e
SI2928454T1 (sl) Triazini za zdravljenje protozojskih bolezni
EP3001837A4 (en) Biological therapeutics for infection-relating disorders or conditions
PT2861242T (pt) Disfunções relacionadas com o glúten
HUE042199T2 (hu) Pantotenát-származékok neurológiai rendellenességek kezelésére
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
PT2872131T (pt) Oleaceína para tratamento ou prevenção de doenças resultantes de placas ateroscleróticas
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
EP2958570A4 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees